A first-in-human, Phase I, dose-escalation study of TAK-117, A selective PI3Ka isoform inhibitor, in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 23, Issue 17, 2017, Pages 5015-5023

  Juric, Dejan ^a   De Bono, Johann S ^b   LoRusso, Patricia M ^c   Nemunaitis, John ^d   Heath, Elisabeth I ^e   Kwak, Eunice L ^a   Mercade, Teresa Macarulla ^f   Geuna, Elena ^g   De Miguel Luken, Maria Jose ^b   Patel, Chirag ^h   Kuida, Keisuke ^h   Sankoh, Serap ^h   Westin, Eric H ^h   Zohren, Fabian ^h   Shou, Yaping ^h   Tabernero, Josep ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c YALE UNIVERSITY   (United States)

^d Mary Crowley Cancer Research Centers   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g CANDIOLO CANCER INSTITUTE   (Italy)

^h MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE ALPHA; SERABELISIB; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG ABSORPTION; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PHASE 1 CLINICAL TRIAL; PI3K/AKT SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY FAILURE; SIDE EFFECT; SOLID MALIGNANT NEOPLASM; TUMOR LOCALIZATION; VERY ELDERLY; VOMITING; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; GENETICS; NEOPLASM; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 85026509256     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2888     Document Type: Article

References (34)

1. Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014; 13:140-56.
2. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8:627-44.
3. Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. The emerging mechanisms of isoform-specific PI3K signalling. Nat Rev Mol Cell Biol 2010; 11:329-41.
4. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27:5497-510.
5. Ollikainen M, Gylling A, Puputti M, Nupponen NN, Abdel-Rahman WM, Butzow R, et al. Patterns of PIK3CA alterations in familial colorectal and endometrial carcinoma. Int J Cancer 2007; 121:915-20.
6. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68:6084-91.
7. Vogt PK, Hart JR, Gymnopoulos M, Jiang H, Kang S, Bader AG, et al. Phosphatidylinositol 3-kinase: the oncoprotein. Curr Top Microbiol Immunol 2010; 347:79-104.
8. Jimeno A, Shirai K, Choi M, Laskin J, Kochenderfer M, Spira A, et al. A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Ann Oncol 2015; 26:556-61.
9. Levy B, Spira A, Becker D, Evans T, Schnadig I, Camidge DR, et al. A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer. J Thorac Oncol 2014; 9:1031-5.
10. Matulonis U, Vergote I, Backes F, Martin LP, McMeekin S, Birrer M, et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol 2015; 136:246-53.
11. Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR, et al. Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol 2015; 17:1270-4.
12. Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, et al. First-inhuman phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2015; 21:77-86.
13. Shapiro GI, Bell-McGuinn KM, Molina JR, Bendell J, Spicer J, Kwak EL, et al. First-in-human study of PF-05212384 (PKI-587), a small-molecule, intravenous, dual inhibitor of PI3K and mTOR in patients with advanced cancer. Clin Cancer Res 2015; 21:1888-95.
14. Tolaney S, Burris H, Gartner E, Mayer IA, Saura C, Maurer M, et al. Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2015; 149:151-61.
15. Vansteenkiste JF, Canon JL, Braud FD, Grossi F, de Pas T, Gray JE, et al. Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study. J Thorac Oncol 2015; 10:1319-27.
16. Jessen K, Kessler L, Kuchareski J, Guo X, Staunton J, Elia M, et al. INK1117: a potent and orally efficacious PI3Ka-selective inhibitor for the treatment of cancer. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia, PA: AACR; Cancer Res 2011; 71(8 suppl): abstract nr 4501.
17. Zopf C, Patel M, Kadakia E, Fabry R, Chakravarty A, Chowdhury S, et al. Combination schedule optimization through preclinical PK-efficacy modeling of an investigational novel-novel combination: a case study of MLN0128 an mTORC1/2 inhibitor with MLN1117 a PI3Ka isoform selective inhibitor. In: Proceedings of the AACR-NCI-EORTC International Conference; 2013 Oct 19-23; Boston, MA. Philadelphia, PA: AACR; Mol Cancer Ther 2013; 12(11 suppl): abstract nr A216.
18. Kadakia E, Iartchouk N, Kannan K, Song K, Zhang DM, Zopf C, et al. Application of preclinical combination pharmacokinetic(PK)/efficacy(E) modeling to investigate and translate the preclinical scheduling effect for MLN1117 and Taxotere combination. In: Proceedings of the AACR-NCI-EORTC International Conference; 2015 Nov 5-9; Boston, MA. Philadelphia, PA: AACR; Mol Cancer Ther 2015; 14(12 suppl 2): abstract nr B154.
19. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47.
20. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, et al. Use ofa monoclonal anti-estrogen receptor antibodyinthe immunohistochemical evaluation of human tumors. Cancer Res 1986; 46:4244s-8s.
21. Ando Y, Inada-Inoue M, Mitsuma A, Yoshino T, Ohtsu A, Suenaga N, et al. Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Cancer Sci 2014; 105:347-53.
22. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 2012; 30:282-90.
23. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, et al. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2012; 18:4173-82.
24. Rodon J, Brana I, Siu LL, DeJonge MJ, Homji N, Mills D, et al. Phase Idoseescalationand-expansionstudy of buparlisib (BKM120), anoral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. Invest New Drugs 2014; 32:670-81.
25. Shapiro GI, Rodon J, Bedell C, Kwak EL, Baselga J, Brana I, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245408 (XL147), an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2014; 20:233-45.
26. Will M, Qin AC, Toy W, Yao Z, Rodrik-Outmezguine V, Schneider C, et al. Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. Cancer Discov 2014; 4:334-47.
27. Mukohara T. PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast Cancer (Dove Med Press) 2015; 7:111-23.
28. Wallin JJ, Guan J, Prior WW, Lee LB, Berry L, Belmont LD, et al. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo. Clin Cancer Res 2012; 18:3901-11.
29. Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer 2013; 20:R83-99.
30. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014; 26:136-49.
31. Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Sci Signal 2014; 7: ra29.
32. West KA, Sianna Castillo S, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002; 5:234-48.
33. Burris HA III. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol 2013; 71:829-42.
34. Fekete M, Santiskulvong C, Eng C, Dorigo O. Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells. Anticancer Res 2012; 32:445-52.